Chardan Capital Initiates Ocular Therapeutix (OCUL) With a Buy Rating

Ocular Therapeutix, Inc. (NASDAQ:OCUL) is one of the Best Performing Long Term Stocks According to Analysts. On September 15, Daniil Gataulin from Chardan Capital initiated Ocular Therapeutix, Inc. (NASDAQ:OCUL) with a Buy rating and a $21 price target.

The analyst highlighted the company’s Axpaxli program, which is the company’s lead program and is being gradually launched over several months. Axpaxli aims to reduce the treatment burden for patients who need frequent anti-VEGF injections. These injections are commonly used for wet age-related macular degeneration and non-proliferative diabetic retinopathy. The analyst believes Axpaxli has significant potential to improve patient outcomes by lowering how often treatments are required. Gataulin suggests that this could make it a valuable option in the eye care market and the gradual release strategy allows Ocular Therapeutix, Inc. (NASDAQ:OCUL) to manage supply and uptake effectively.

Ocular Therapeutix, Inc. (NASDAQ:OCUL) is a biopharmaceutical company focused on eye diseases. It develops sustained-release drug treatments using its ELUTYX hydrogel technology.

While we acknowledge the potential of OCUL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.